Can Patients with Multiple Sclerosis Present with Headache?
Yes, patients with multiple sclerosis frequently present with headache, with prevalence rates of 50-60% reported in MS populations—significantly higher than healthy controls. 1, 2
Headache Prevalence and Types in MS
Headache is a common and often underrecognized manifestation in MS patients:
- Overall headache prevalence: 54-58% in MS patients versus 43.5% in healthy controls 1, 3
- Migraine: Occurs in approximately 16-30% of MS patients, with a significant association (OR = 2.02) compared to controls 1, 3
- Tension-type headache (TTH): Affects 19-24% of MS patients, significantly more common than in controls (16.7%) 1, 4
The evidence demonstrates that MS patients are twice as likely to experience migraine as controls 3, though this relationship requires careful interpretation given methodological limitations in existing studies.
Clinical Context and Timing
Headache in MS can manifest in several distinct patterns:
- Prodromal symptom: May precede MS diagnosis by several years as part of the non-specific prodromal phase 2
- Associated with relapses: Can occur during acute MS exacerbations 5
- Chronic comorbidity: Develops during the disease course independent of relapse activity 5
Importantly, headache alone is NOT considered a typical demyelinating presentation for MS diagnosis. The diagnostic criteria require typical clinical syndromes such as optic neuritis, incomplete transverse myelitis, or brainstem syndromes 6. Application of diagnostic criteria with atypical presentations like isolated headache increases misdiagnosis risk 6.
Anatomical Correlations
MRI findings suggest specific patterns:
- Brainstem lesions: Predominance of inflammatory lesions in the brainstem, particularly periaqueductal gray matter, correlates with headache frequency 4, 5
- Periaqueductal gray involvement: Found in 40% of patients experiencing headaches on >10 days per month 4
- Sensorimotor lesions: Present in 53.4% of patients with severe headaches 4
Disease-Modifying Therapy Considerations
Critical caveat: Several MS disease-modifying therapies can induce or worsen headache:
- Headache-inducing agents: Interferons (OR 2.84-3.72 for worsening headaches), teriflunomide, ponesimod, alemtuzumab, cladribine, and fingolimod 4, 2
- Protective agents: Rituximab associated with decreased headache risk (OR 0.04-0.09) 4
Differential Diagnosis Requirements
Before attributing headache to MS, exclude secondary causes:
- Aseptic or septic meningitis
- Cerebral venous sinus thrombosis (especially with antiphospholipid antibodies)
- Cerebral or subarachnoid hemorrhage
- Medication overuse headache
- Cervical trauma
- Psychiatric disorder-associated headaches 7, 5
Clinical Patterns by MS Phenotype
- TTH predominates in: Males, higher disability (EDSS ≥3), progressive MS phenotypes (SPMS, PPMS) 4
- Migraine predominates in: Females, milder disability (EDSS <3), relapsing-remitting MS 4
Management Implications
Headache in MS patients should be diagnosed and treated according to standard headache classification criteria (ICHD-3), not as a direct MS symptom 8, 5. Standard migraine therapies remain appropriate, though medication selection should consider:
- Potential interactions with disease-modifying therapies
- Avoidance of medication overuse
- Individual MS-related contraindications
The relationship between MS and headache remains incompletely understood, likely involving shared demographic factors (female predominance), hormonal influences, and psychological features (anxiety, depression) common to both conditions 5.